Page 9 - Pharma Stocks

Nifty Pharma index slips 3%; Natco, Glenmark, Lupin, Laurus down up to 10%

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

PI Industries hits 52-week low; down 11% in one week on poor Q3 earnings

PI Industries' steady Q3FY25 performance, cautious near-term outlook, and portfolio challenges are likely to affect the business dynamics in FY26 and FY27, according to analysts.

FDC hits 52-week low, stock slips 9% on weak Q3 results

EBITDA for Q3FY25 was impacted by lower sales in export formulation biz, price reduction in the Electral range of products, driven by NLEM price revisions changes in the product mix, and higher cost.

Analysts bullish on Lupin after Q3; share pops 6%; Goldman Sachs ups target

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising product pipeline

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

Ami Organics extends rally on strong Q3 results; stock zooms 30% in 4 days

The management believes, that on account of ramp-up of existing products, Fermion contract, and potential commercialisation of another CDMO contract in FY26E, Ami has strong revenue visibility.

Senores Pharmaceuticals races 17% on robust Q3; profit more than doubles

The rise in Senores Pharmaceuticals share came after the company's strong show in the December quarter (Q3FY25) results

Neuland Labs gets capex nod lift; stock up 5% even as broader indices sink

The company said it will spend Rs 254 crore for development and commercial production of Peptides for Generic Drug Substances (GDS) and Custom Manufacturing Solutions (CMS) business.

Indoco Remedies drops 4% on weak Q3 performance; revenue falls 11% YoY

Indoco Remedies share dropped after the company reported a weak set of numbers in the December quarter of financial year 2025 (Q3FY25)

Venus Remedies share price surges 12% on renewal of EU GMP certification

The rise in Venus Remedies share price came after the company announced the renewal of its European GMP certification by Infarmed, the National Authority of Medicines and Health Products in Portugal

Glenmark Pharma share rises 2% as unit launches blood clotting drug

The uptick in Glenmark Pharmaceuticals share price came after the company announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules

Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

AstraZeneca Pharma share price rises 3% on CDSCO nod for Eculizumab

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO

Biocon extends rally, up 6% in 2 days on HSBC, Motilal Oswal 'Buy' upgrade

Notably, Biocon share price has surged about 6 per cent in the last two sessions

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

Nifty outlook indecisive, says Vinay Rajani; picks 2 stocks to buy today

Stocks to Buy Today: Narayana Hrudalaya and Pfizer shares have been rising with heavy volumes

Laurus Labs hits 2-yr high on hopes of healthy earnings; up 44% in 3 months

The board of directors of Laurus are scheduled to meet on January 24 to announce the financial results of the company for the quarter ended December 31, 2024.

Aarti Pharma share price down 5% from day high on order to shut Vapi plant

Aarti Pharma share price: The Gujarat Pollution Control Board has ordered Aarti Pharma to deposit a bank guarantee of Rs 2,50,000

Supriya Lifescience share price soars 7% in weak market today; here's why

Supriya Lifescience Chairman and Whole-Time Director Satish Wagh said he was confident of achieving 22 per cent year-on-year revenue growth in the current financial year (FY25)